(Source: MorphoSys AG) November 05, 2015 / 4:30 pm, CET MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX, OTC: MPSYY) today announced upcoming presentations of data on the Company's proprietary programs at the 57th American Society of Hematology (ASH) Annual Meeting, being held December 5-8, 2015 in Orlando, Florida. Presentations will feature pre-clinical and clinical data for MorphoSys's proprietary programs MOR208 and MOR202. 'We believe the promising new pre-clinical and clinical data being presented for our proprietary portfolio will further demonstrate the potential of MOR208 and MOR202 as important treatment options for patients with B-cell malignancies and multiple myeloma,...
↧